Self-limited neonatal-infantile epilepsy

Self-limited neonatal-infantile epilepsy (previously known as benign familial neonatal-infantile epilepsy or BFNIE) is a rare genetic epilepsy syndrome characterized by seizures that begin in the neonatal or early infantile period, typically between the first few days of life and 12 months of age. The condition primarily affects the central nervous system, with seizures that may present as focal or generalized tonic-clonic episodes, often occurring in clusters. Between seizures, affected infants typically have normal neurological examinations and normal development. The hallmark of this condition is its self-limited course — seizures generally resolve spontaneously by 12 to 24 months of age, and long-term neurodevelopmental outcomes are usually favorable, with most children achieving normal cognitive and motor development. The most commonly implicated gene is SCN2A, which encodes a voltage-gated sodium channel subunit (Nav1.2) critical for neuronal signaling. Mutations in KCNQ2 and KCNQ3 have also been associated with overlapping phenotypes in the neonatal-infantile epilepsy spectrum. Treatment during the active seizure phase typically involves antiseizure medications such as carbamazepine, oxcarbazepine, or phenobarbital, which are generally effective in controlling seizures. Given the self-limited nature of the condition, antiepileptic therapy is usually tapered and discontinued after a seizure-free period, often by 12 to 24 months of age. Genetic counseling is recommended for affected families due to the hereditary nature of the disorder. Electroencephalography (EEG) findings may be normal or show mild focal or multifocal abnormalities during the active phase, and brain MRI is typically normal.

Common questions about Self-limited neonatal-infantile epilepsy